Cyltezo® Pen (adalimumab-adbm) Injection
The Cyltezo® Pen was designed with patients in mind, with a 1 button, 3-step activation.
Cyltezo®, developed by Boehringer Ingelheim, is an Interchangeable Biosimilar to Humira that may treat or reduce the signs and symptoms of certain autoimmune conditions, like Rheumatoid Arthritis, Crohn’s Disease, and Psoriasis. Cyltezo® can be administered with a Cyltezo® pre-filled syringe, or with the Cyltezo® Pen. The Cyltezo® Pen was designed with patients in mind, with a 1 button, 3-step activation. Features and details include 100% drug visibility, passive needle shielding, protected needle at all times, start of injection indicator: click noise, and end of injection indicator: stopper at the bottom of the barrel.